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Abstract
The founding tenet of evidence-based medicine is to combine best evidence with clinical expertise. As David Sackett
opined ‘Without clinical expertise, practice risks becoming tyrannised by evidence’. Rigid protocols and mandates,
based on an inconclusive and low-level evidence base, cannot suit the physiological, biochemical and biological
heterogeneity displayed by the individual septic patient. Indeed, clear proof of outcome benefit through adoption of
an inflexible management approach is lacking and will certainly be detrimental to some. Therapy thus needs to be
tailored to meet the individual patient’s needs. The same principle should be applied to clinical trials; the continued
disappointments of multiple investigational strategies trialled over three decades, despite (often) a sound biological
rationale, suggest a repeated methodological failure that does not account for the marked heterogeneity within the
septic patient’s biological phenotype and thus marked variation in their host response. The increasing availability of
rapid point-of-care diagnostics and theranostics should facilitate better patient selection and titrated optimization of
the therapeutic intervention.
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Introduction
The history of intensive care has been littered with too
many false dawns. Old management dogma, now de-
rided, have been replaced by new and equally resolute
convictions, many of which will, in time, undoubtedly
follow a similar course. Retired bundles of care have
been replaced by new bundles driven by clinical evange-
lists and government diktat. Yet these too lack a strong
evidence base and can be readily challenged. Homo-
genizing treatment given to a highly heterogenous
patient population that fall under the wide syndromic
umbrella of sepsis may offer a minimum standard of
care though at the potential cost of compromising out-
comes in an individual patient. Likewise, the repeated
multicentre trial failures of novel interventional stra-
tegies over many decades highlight the need to focus
more precisely on the individual’s biological phenotype
and adopt a personalized treatment approach. This
article will briefly cover these issues and offer directions
for the future.
Guidelines or rules-of-stone?
Evidence-based medicine is intended to offer best treat-
ment and represents a worthy aim to raise standards
and homogenize care. It offers a framework when basic
expertise is lacking. An excellent example is the
Advanced Trauma Life Support course, established by
an orthopaedic surgeon (James Styner) after a plane
crash in rural Nebraska in 1976 on finding medical care
for his injured children was disorganized and subopti-
mal. However, one size does not, and should not, fit all.
While providing structure is clearly important, especially
for less-experienced healthcare providers, it must be
tailored to the individual patient. To cite David Sackett,
one of the ‘godfathers’ of evidence-based medicine [1]:
‘Good doctors use both individual clinical expertise
and the best available external evidence, and neither
alone is enough. Without clinical expertise, practice
risks becoming tyrannised by evidence, for even
excellent external evidence may be inapplicable to or
inappropriate for an individual patient.’
‘Evidence based medicine is not “cookbook” medicine.
Because it requires a bottom up approach that
integrates the best external evidence with individual
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clinical expertise and patients’ choice, it cannot result
in slavish, cookbook approaches to individual patient
care. External clinical evidence can inform, but can
never replace, individual clinical expertise, and it is
this expertise that decides whether the external
evidence applies to the individual patient at all and, if
so, how it should be integrated into a clinical decision.
Similarly, any external guideline must be integrated
with individual clinical expertise in deciding whether
and how it matches the patient’s clinical state,
predicament, and preferences, and thus whether it
should be applied. Clinicians who fear top down
cookbooks will find the advocates of evidence based
medicine joining them at the barricades.’
Septic patients, especially when critically ill, represent a
highly heterogenous population. It is over-simplistic to
believe that the same strategy will benefit every patient as
their underlying physiological reserve, underlying comor-
bidities, presenting physiology, unmeasured biological
phenotype and response to drugs, fluids and other thera-
pies will all vary markedly. Temporal variations during the
acute illness must also be taken into consideration.
Sepsis management guidelines are worthy but, un-
fortunately, often taken too literally by clinical evan-
gelists, hospitals, government bodies, lawyers and
litigators with financial penalties, litigation and public
‘naming-and-shaming’ for non-compliant miscreants.
Guidelines are thus forced into rigid protocols with
little room for clinical judgement to be applied. We
must acknowledge there is still no ‘right’ way to manage
all the complexities of a septic patient. The overall
evidence base for sepsis remains weak as shown by the
limited number of ‘high-quality’ recommendations made
by the Surviving Sepsis Campaign (SSC) [2]. Indeed, these
recommendations mainly relate to interventions we
should not do, rather than those we should. These guide-
lines are based on current consensus but, as the che-
quered history of sepsis management clearly shows,
today’s strong belief is often tomorrow’s discard. The
now-abandoned SSC 6-h and 24-h management bundles
were heavily touted as ‘a group of interventions related to
a disease process that, when executed together, result in
better outcomes than when implemented individually.
The individual bundle elements are built upon evidence-
based practices. The science behind the elements of a
bundle is so well-established that their implementation
should be considered a generally accepted practice’ [3].
We were warned: ‘If all of the elements of the bundles are
not incorporated .. your performance on the measures will
suffer’ [3]. Unfortunately, this quasi-religious fervour has
not been borne out by subsequent multicentre studies that
failed to reproduce the original study findings, for example
early goal-directed therapy [4, 5].
No one will argue that early identification and prompt,
appropriate management are not important cornerstones
of good treatment. However, what constitutes ‘appropri-
ate’ is moot. For example, a fixed volume 30ml/kg fluid
resuscitation regimen within the current SSC bundle [2]
will under-treat some yet over-treat others [6]. Patients
cannot benefit from fluid overload [7], in much the
same way that oxygen overload (hyperoxia)—an abso-
lute iatrogenic phenomenon—is increasingly recognized
as being harmful [8, 9].
A post hoc analysis [6] of the VASST trial, comparing
vasopressin against norepinephrine in patients with
septic shock, highlighted the increasing severity-adjusted
mortality risk related to an increasing fluid balance, both
at 12 h and 72 h after ICU admission (Table 1). Sicker
patients will generally need more fluid than the less sick.
However, while severity adjustment cannot account for
all possible confounding factors, the disparity in fluid
volumes given does strongly suggest a contribution to
mortality from excess fluid. It is more rational to utilize
appropriate monitoring to titrate fluid input to meet the
needs of the patient in terms of adequacy of organ
perfusion, rather than using an empiric, formulaic,
unphysiologic approach.
Likewise, antibiotics are thrown around indiscri-
minately and often to patients who are not septic and
thus cannot gain from an inappropriate intervention. In
different studies, only 57–80% of patients treated for
suspected sepsis or admitted to intensive care units with
septic shock were subsequently adjudicated as having
‘definite’ or ‘probable’ sepsis [10–12]. As discussed
below, the evidence for benefit from early antibiotics in
Table 1 Relationship between fluid balance and mortality—retrospective analysis of the VASST study. Adapted from Boyd et al. [7]
Quartile 1 Quartile 2 Quartile 3 Quartile 4
12-h fluid balance 710 (− 132–1480) 2880 (2510–3300) 4900 (4290–5530) 8150 (7110–10,100)
4-day fluid balance 1560 (− 723–3210) 8120 (6210–9090) 13,000 (11,800–14,700) 20,500 (17,700–24,500)
Adjusted hazard ratio
vs quartile 4
- 12 h 0.57 (0.41–0.80) 0.58 (0.41–0.82) 0.76 (0.56–1.03) –
- 4 days 0.47 (0.30–0.72) 0.51(0.34–0.78) 0.74 (0.50–1.09) –
Volumes expressed as median (inter-quartile range)
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non-shock patients is questionable, and the propensity
to harm significant yet under-recognized.
Despite this, a 2018 update from the SSC leadership
argued that ‘the compelling nature of the evidence in the
literature, which has demonstrated an association between
compliance with bundles and improved survival in
patients with sepsis and septic shock’ should mandate
clinicians to combine the previous 3- and 6-h bundles into
a single 1-h bundle, with time zero defined as the time of
triage in the emergency department [13]. This 2018 guide-
line generated a fierce reaction particularly from the
Emergency Medicine community, including an online
campaign demanding retraction; at the time of writing,
this petition had amassed over 6000 signatures [14].
Do mandates work?
In the USA, Medicare/Medicaid has imposed ‘SEP-1’
(Sepsis National Hospital Inpatient Quality Measure) on
emergency departments. This requires documentation of
procedures that must be rigidly performed in patients
with suspected sepsis, and detailed written justifications
where any deviation occurs. Though currently used for
reporting purposes, this is likely to be soon applied to
hospital re-accreditation and reimbursement. A recent
systematic review concluded that ‘no high- or moderate-
level evidence shows that SEP-1 or its hemodynamic
interventions improve survival in adults with sepsis’
[15]. The authors noted that SEP-1 requires reporting of
up to five haemodynamic interventions, as many as
141 tasks, and as long as 3 h of documentation time
for a single patient.
The National Health Service in England withholds 4% of
each hospital’s budget with 1% being returned when
targets are met for each of four annual CQUINs (quality
improvement initiatives). A current CQUIN [16] requires
use of early antibiotics within an hour of diagnosis of
sepsis in emergency department patients. While an
improvement over a previous mandate of ‘one hour from
hospital arrival’, this has still driven a marked increase in
use of antibiotics in the emergency department, in
particular with agents such as meropenem and piptazo-
bactam that, ironically, the CQUIN also seeks to restrict
because of valid concerns over antimicrobial resistance.
This strategy has failed to show any clear outcome benefit;
in patients with a suspicion of sepsis admitted to English
hospitals as emergencies, the number of hospital deaths,
ICU bed days and 30-day readmission rates have not
fallen [17]. Sadly, anecdotal evidence from some hospitals
suggests antibiotics are being prescribed to meet these
financial/quality improvement targets, even before the
patient has been reviewed by a doctor.
From 2013, the New York State Department of Health
required hospitals to follow ‘evidence-informed protocols’
based on the SEP-1 mandate for the early identification
and treatment of sepsis. All hospitals were required to
include a 3-h bundle with blood culture collection before
administration of antibiotics, measurement of serum
lactate and administration of broad-spectrum antibiotics,
and a 6-h bundle requiring intravenous administration of
30ml fluid/kg body weight in patients with hypotension
or a serum lactate ≥ 4mmol/l, initiation of vasopressors
for refractory hypotension and re-measuring lactate
within 6 h.
The headline finding of a retrospective analysis of
49,331 presumed septic patients in the New York State
database [18] found patients had a higher risk-adjusted,
in-hospital mortality (odds ratio 1.04 per hour; 95% CI,
1.03–1.06; p < 0.001) related to delayed administration of
antibiotics. However, closer scrutiny of the presented
data generates significant concerns as to the plausibility
of this conclusion. The protocol was initiated within a
6-h window after arrival in the emergency department,
rather than beginning at the time of entry. Actual
in-hospital death was 22.6% in those completing the
bundle within 3 h versus 23.6% in those completing
between 3 and 12 h. Timing of receipt of a 30 ml/kg
fluid bolus over the 12-h period made no difference to
mortality despite nearly half the patients having ‘septic
shock’ based on the old Sepsis-2 classification. No bene-
fit was seen with timely antibiotics in patients with
Gram-positive bacteraemia, and a small benefit was seen
with Gram-negative bacteraemia or where no organisms
were found. Yet the greatest benefit in terms of
risk-adjusted in-hospital mortality (odds ratio 1.15 per
hour; 95% CI, 1.07–1.24) was found in ‘other’ bacterae-
mias that comprised anaerobic, mixed, viral, fungal and
yeast cultures. Appropriateness of antibiotics and source
control were not evaluated, and confirmation of true
sepsis (based on discharge coding) was not performed.
Tellingly, benefit was only seen from early bundle com-
pletion in the third of the patient population receiving
vasopressors; no mortality improvement was seen in the
other two thirds. Indeed, another retrospective analysis
based on septic patients presenting to the Kaiser Perma-
nente hospital group in Northern California reported a
similar effect [19].
Crucially, every prospective study specifically addres-
sing the question of antibiotic delay and outcome fails to
show a temporal relationship between early antibiotics
and improved survival [20]. What support there is
derives from heavily adjusted retrospective analyses of
incomplete databases usually collected for other reasons.
Even then, the findings are inconsistent [21]. Reasons for
delay in delivering antibiotic treatment have also not
been ascertained and may be highly pertinent. For
example, Filbin et al. recently reported that a third of
patients presenting to an emergency department with
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septic shock had vague symptoms not specific to infec-
tion and this represents a previously unrecognized con-
founder [22]. Notably, a recent paper surveying deaths
in six US hospitals found sepsis was present in half the
cases and a direct cause of death in a third, yet only
3.7% of the sepsis-associated deaths were adjudged
definitely or moderately preventable [23].
There are other examples of a rigid, protocolized
approach not yielding outcome dividends. Patients in
three prospective multicentre studies [5] assessing the
Rivers Early Goal-Directed Therapy strategy [4] failed to
show any benefit over standard-of-care. Multicentre
trials in African adults [24] and children [25] with sepsis
showed worse outcomes when applying a Western-based
protocolized approach to management, perhaps related
to a logistic inability to deal with iatrogenic compli-
cations induced by the approach.
In summary, guidelines are valuable as an aide mem-
oire, but the evidence that strict protocols that demand
homogenized management result in outcome benefit is
weak at best. Excessive delay is not warranted and, per-
haps analogous to managing haemorrhage, the speed of
response in an individual septic patient is likely best dic-
tated by their severity [26]. Logically, treatment should
be tailored to meet the individual’s needs and underlying
comorbidities.
Repeated trial failures
The last three decades have seen a litany of failed trials
of various immunomodulatory and other therapies des-
pite encouraging preclinical data [27]. The methodolo-
gies and translatability of many of the underpinning
animal models must be challenged as being unfit for
purpose [28]. Yet the question must still be posed as to
why all have failed to show any outcome benefit when
trialled in patients despite a sound scientific rationale
and decent proof-of-principle. It is convenient to blame
the drug or intervention, but perhaps more focus needs
to be placed on the study design itself. To satisfy the
great god ‘p’, large numbers of patients need to be
recruited into Phase III trials. This drives enrolment of a
highly heterogenous population of septic patients in
terms of age, underlying comorbidities and source, type
and duration of infection, not to mention potential iatro-
genic confounders, e.g. variability and/or appropriate-
ness of antibiotics, source control, fluid and vasopressor
therapy and ventilator settings. To use but one example,
immune function markedly changes with age in healthy
subjects [29]. The impact of age has been elegantly
demonstrated in preclinical studies where a positive out-
come response to antibiotics in young (6–12 weeks old)
mice could not be reproduced in an aged (20–24
months) population [30].
Benefit from an intervention in one septic subset may
be negated by harm in another, or diluted out by non-ef-
fect in a majority subset. This is well illustrated by the
SEPSISPAM study [31] where patients were randomized
to a high or low mean blood pressure target regardless
of their underlying normal blood pressure. No overall
mortality difference was noted, yet the likely benefit on
renal function of having a higher blood pressure in
chronically hypertensive patients was counterbalanced
by a harmful signal in normotensives, likely related to
injurious side effects of unnecessarily excessive vasopres-
sor doses [32].
It is becoming increasingly apparent that standard
physiological and biochemical variables relate poorly to the
underlying biological phenotype/endotype/subendotype of
the patient. Studies using various ‘omic’ (transcriptomic,
metabolomics, proteomic) approaches (e.g. [33–35]) as
well as a host of biomarker studies (e.g. [36–38]) demon-
strate clear prognostic differences using samples collected
even as early as the emergency department. As a useful
generalization, eventual non-survivors tend to show a more
extreme signature. Other biomarker studies in sepsis and
ARDS, albeit using retrospective analyses of trial databases,
demonstrate highly variable host and outcome responses
to the studied intervention (e.g. fluid, PEEP, corticosteroids,
statins) with benefit in some subsets and even harm in
others [39–42]. Yet, drug and device trial interventions
are generally based on a fixed one-size-fits-all regimen
with no consideration given to the patient’s underlying
biological phenotype.
As an example, those with a strong pro-inflammatory
phenotype may benefit from an appropriate degree of
suppression [43]. However, the same dosing regimen
may result in excessive suppression in those with a
less-pronounced pro-inflammatory signature which can
result in an increased propensity to secondary infection/
sepsis and, potentially, an increased risk of death. This
may explain the variable results seen with corticosteroids
which, in recent systematic reviews, appear to give a
small degree of survival benefit to patients with septic
shock but harm to non-shocked patients [44]. Septic
shock patients are more likely to possess a greater
pro-inflammatory phenotype [39]. Yet, even within this
cohort, the biological signature, and thus the response to
the intervention, is still likely to be highly variable.
The advent of rapid point-of-care diagnostics will facilitate
appropriate selection of biologically suitable patients into
studies, and optimization of drug dosing (when, by how
much and for how long). There is no guarantee of success
as the derangement in biomarker level may be epipheno-
menal rather than integral to a causative pathway, or may
even be part of an adaptive process. However, the theranos-
tic targeting of a specific biomarker can be tested a priori
for proof-of-principle in appropriate animal models [43].
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